Compare KGS & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KGS | CORT |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | 2023 | 2001 |
| Metric | KGS | CORT |
|---|---|---|
| Price | $75.73 | $56.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | $57.17 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 1.3M | 974.9K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | ★ 58.93 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $1,308,100,000.00 | $761,407,000.00 |
| Revenue This Year | $12.30 | $26.08 |
| Revenue Next Year | $7.96 | $26.98 |
| P/E Ratio | $375.50 | ★ N/A |
| Revenue Growth | ★ 12.83 | 12.79 |
| 52 Week Low | $30.06 | $28.66 |
| 52 Week High | $76.68 | $91.00 |
| Indicator | KGS | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 79.56 | 78.42 |
| Support Level | $33.33 | $32.95 |
| Resistance Level | N/A | $90.00 |
| Average True Range (ATR) | 2.40 | 2.16 |
| MACD | 0.57 | 0.34 |
| Stochastic Oscillator | 92.24 | 91.49 |
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Contract Services and Other Services. Contract Services consists of operating Company-owned and customer-owned compression, and gas treating and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.